CA-ENCHROMA
14.12.2022 08:01:37 CET | Business Wire | Press release
The Centre Pompidou today announced that colour blind visitors are now able to borrow EnChroma glasses for colour blindness during visits to the iconic museum. The Centre Pompidou is internationally renowned for its collection of modern and contemporary art totaling over 120,000 works – the most extensive in all of Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221213006029/en/
Robert Delaunay, Manège de cochons, 1922. Don de Mme Sonia Delaunay en 1956. Centre Pompidou, Paris, Musée national d’art moderne - Centre de création industrielle. Colour blind view courtesy of EnChroma. (Graphic: Business Wire)
One in twelve men (8%) and one in 200 women (0.5%) are colour blind – about 2.8 million in France, 30 million in Europe and 350 million globally. With over three million annual visitors, an estimated 128,000 guests to the Centre Pompidou are colour blind. EnChroma glasses will enable colour blind visitors to perceive an expanded range of clear, vibrant colour in artwork at the museum for the first time in their lives.
“Always concerned with offering the best visitor experience to all audiences, the Centre Pompidou is delighted to offer people with colour blindness the possibility of trying EnChroma glasses, a very innovative device in the museum sector,” said David Cascaro, Director of the Public Division, Centre Pompidou.
While people with normal colour vision see over one million shades and hues of colour, colour blind people see only an estimated 10% of them. To the red-green colour blind, colours appear dull and washed out, with some difficult to distinguish from each other. Common colour confusions include green and yellow, grey and pink, purple and blue, and red and brown. This can detract from the ability of colour blind people to fully experience colourful art.
"We are thrilled that one of the world’s foremost visionaries in arts and culture – the Centre Pompidou – is demonstrating its commitment to accessibility and inclusion for those with colour vision deficiencies by loaning EnChroma glasses to guests," said Erik Ritchie, CEO of EnChroma. “Their example will generate more awareness for the prevalence and effects of colour blindness, inspire other museums and organizations to follow their lead, and ultimately expand opportunities for colour blind people to more fully experience colorful, iconic artwork like never before.”
The Centre Pompidou is the first museum in France to support the needs of colour blind guests via the EnChroma Colour Accessibility Program™. The program already helps colour blind people at nearly 200 public institutions – including libraries, schools, universities, national parks, gardens, tourism bureaus and 80+ major museums – more fully experience colours in art, nature and overcome obstacles to learning. Other museums participating in the program include the Gallerie d’Italia in Italy, the Chau Chak Wing Museum in Australia, Centraal Museum Utrecht in The Netherlands, and the Georgia O’Keeffe Museum, Dallas Museum of Art, and Crystal Bridges Museum of American Art in the US.
Special optical filters in EnChroma glasses help colour blind people perceive a wider range of colours and see them more vividly and distinctly. A study by the University of California, Davis, and INSERM, the French National Institute for Health and Medical Research, demonstrated the effectiveness of EnChroma glasses. A separate recent study in the scientific publication Eye-Nature also highlights the benefits of the glasses.
EnChroma Colour Accessibility Program™
EnChroma is the leading advocate for accessibility for those with colour blindness. The company donates a pair of glasses for every pair an organization purchases. EnChroma also provides materials for institutions to educate the public or teachers, students and parents about colour blindness and its effects. Public organizations interested in the EnChroma Program can email accessibility@enchroma.com.
About the Centre Pompidou
Since 1977, the Centre Pompidou has been deeply rooted in the city of Paris and open to the world and to innovation. Its iconic building is home to Europe's richest and one of the world's largest collections of modern and contemporary art, in addition to exhibitions, symposiums, festivals, shows, projections, and workshops for young people. Its extremely rich programme at the crossroads of art forms and audiences attracts more than 3.5 million visitors every year. True to its ambition to make culture and creation available to as many people as possible, the Centre Pompidou also develops its regional and international presence. For more information, visit: centrepompidou.fr.
About EnChroma
Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Visit enchroma.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213006029/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
